Study | Subgroups by MP status | Exposure categories (n) | Highest/lowest exposure category | RR (95% CI) | |
---|---|---|---|---|---|
ER+PR+ | ER-PR- | ||||
Cohort studies | |||||
[9] | Post-MP | 3 | ≥3/Nulliparous | 0.75 (0.52–1.06) | 2.24 (0.69–7.24) |
Per birth | 0.96 (0.89–1.03) | 1.09 (0.91–1.30) | |||
[10] | All women | 3 | 4/Nulliparous | 0.74 (0.61–0.89) | 1.17 (0.80–1.70) |
Per birth | 0.88 (0.79–0.98) | 1.13 (0.92–1.41) | |||
Summary RRs for cohort studies | Highest/Nulliparous | 0.74 (0.50–1.10) | 1.25 (0.84–1.87) | ||
Per birth | 0.93 (0.80–1.08) | 1.11 (0.95–1.29) | |||
Population-based case-control studies | |||||
[12] | Young | 2 | Ever/Nulliparous | 0.83 (0.60–1.15) | 0.82 (0.55–1.23) |
Per birth | 0.91 (0.77–1.07) | 0.91 (0.74–1.11) | |||
[13] | All women | 4 | ≥3/Nulliparous | 0.62 (0.43–0.90) | 0.77 (0.46–1.27) |
Per birth | 0.90 (0.82–0.97) | 0.94 (0.84–1.06) | |||
Pre-MP | 4 | ≥3/Nulliparous | 0.44 (0.26–0.75) | 0.90 (0.46–1.76) | |
Per birth | 0.83 (0.73–0.94) | 0.97 (0.83–1.14) | |||
Post-MP | 4 | ≥3/Nulliparous | 0.71 (0.53–0.97) | 0.72 (0.46–1.12) | |
Per birth | 0.92 (0.86–0.98) | 0.93 (0.84–1.03) | |||
[14] | Young | 4 | ≥3/Nulliparous | 1.0 (0.5–1.2) | 0.8 (0.4–1.3) |
Per birth | 1.00 (0.90–1.11) | 0.94 (0.81–1.09) | |||
[7] | All women | 4 | ≥3/Nulliparous | 0.63 (0.54–0.73) | 1.07 (0.86–1.32) |
Per birth | 0.86 (0.82–0.90) | 1.01 (0.95–1.08) | |||
[8] | Young | 4 | ≥3/Nulliparous | 0.61 (0.42–0.88) | 0.93 (0.60–1.44) |
Per birth | 0.86 (0.78–0.95) | 0.95 (0.84, 1.06) | |||
Summary RRs for population-based case-control studies | Highest/Nulliparous | 0.67 (0.55–0.82) | 0.96 (0.79–1.17) | ||
Per birth | 0.88 (0.83–0.94) | 0.98 (0.92–1.04) | |||
Hospital-based case-control study | |||||
[15] | Per birth | Per birth | 0.96 (0.79–1.17) | 1.00 (0.81–1.23) | |
Summary RRs by MP status | Pre-MP/Young | Highest/Nulliparous | 0.72 (0.52–0.98) | 0.86 (0.63–1.18) | |
Per birth | 0.90 (0.82–0.98) | 0.95(0.86–1.04) | |||
Post-MP | Highest/Nulliparous | 0.72 (0.44–1.17) | 0.86 (0.53–1.42) | ||
Per birth | 0.93 (0.84–1.03) | 0.97 (0.88–1.08) | |||
Summary RRs for all studies | Highest/Nulliparous | 0.75 (0.65–0.88) | 1.01 (0.87–1.17) | ||
Per birth | 0.89 (0.84–0.94) | 0.99 (0.94–1.05) | |||
P for homogeneity between ER+PR+ and ER-PR- cancer | Highest/Nulliparous | p <0.001 | |||
Per birth | p <0.001 |